

# **DEVELOPMENT OF NUCLEAR RECEPTOR TRANSFECTED CACO-2 CELL LINES**

Timo Korjamo

University of Kuopio

Finland

27th October 2006


- **Background**
- Cell lines
- Gene expression
- Functional experiments
- Conclusions

# Intestinal absorption

- Small intestine is the most important site of drug absorption → predictions in the discovery phase important
- Intestinal epithelium often limits the absorption rate from GIT
- Active first-pass metabolism


# CYPs and efflux pumps

- Cytochrome P450 (CYP) families 1-3 metabolise several xenobiotic compounds in microsomes of several tissues (e.g. liver, small intestine)
- Efflux-pumps (P-glycoprotein, MRP-family, BCRP) excrete several xenobiotic compounds from the cells




Fricke and Miller Pharmacol Toxicol 2002;90:5-13.

# CYPs / efflux pumps - interplay




# Regulation of xenobiotic metabolism - nuclear receptors



Some target genes:

CYP2B6,  
CYP2C9,  
CYP3A4,  
MDR1

# Average enterocyte?



- Background
- **Cell lines**
- Gene expression
- Functional experiments
- Conclusions

# Caco-2 cells

A colon carcinoma cell line that differentiates spontaneously into enterocyte-like cells

- + Widely used
- + Human origin
- + Expresses many transporters
- + Relatively easy to grow
- Inter and intralaboratory differences
- Paracellular space very tight
- Incomplete transporter profile
- CYP metabolism absent
- Long growth time

About Caco-2 cells in permeability experiments:

Ungell. Drug Discovery Today Technologies 2004(1): 423-430.

# Modified cell lines

Cell line	Modification	Ligands	Some target genes
Caco/WT	Wild type cells		
Caco/hPXR	Transfection with human PXR	+ : Rifampicin, ritonavir, hyperforin	<b>CYP3A4, MDR1, CYP2B6</b>
Caco/mCAR	Transfection with murine CAR	+ : TCPOBOP, phenobarbital - : Androstenol, progesterone	<b>CYP2B6, MDR1, CYP3A4, CYP2C9, MRP2</b>

Initial characterisation:

T. Korjamo, P. Honkakoski, M. R. Toppinen, S. Niva, M. Reinisalo, J. J. Palmgren, and J. Monkkonen. Absorption properties and P-glycoprotein activity of modified Caco-2 cell lines. Eur J Pharm Sci, 26:266-279 (2005).

Induction properties:


T. Korjamo, J. Monkkonen, J. Uusitalo, M. Turpeinen, O. Pelkonen, and P. Honkakoski. Metabolic and efflux properties of caco-2 cells stably transfected with nuclear receptors. Pharm Res, 23:1991-2001 (2006).

- Background
- Cell lines
- **Gene expression**
- Functional experiments
- Conclusions


# Changes in transcription: qRT-PCR

R = hPXR activator rifampicin, T = mCAR activator TCPOBOP, A = mCAR inhibitor androstenol


CYP3A4




CYP2B6



MDR1




# Protein level



- Background
- Cell lines
- Gene expression
- **Functional experiments**
- Conclusions

# Permeability experiments


P-glycoprotein




- Apical to basolateral (AB): "from intestinal lumen to circulation"
- Basolateral to apical (BA): "from circulation to intestinal lumen"
- $P_{AB} > P_{BA}$  -> Active absorption
- $P_{AB} < P_{BA}$  -> Efflux pump (active secretion)
- pH-gradients may cause deviations if ionisable molecules are studied!

# Passive permeability

Antipyrine (transcellular)




Mannitol (paracellular)




# Active absorption

Cephalexin (hPepT1)




# Permeability involving P-gp

Digoxin




# Permeability involving P-gp



# CYP3A4 mediated metabolism

Ketoconazole sensitive HFC formation from BFC



# Conclusions

- Stable transfectants retain viability and passive transport properties
- Genes can be controlled in Caco-2 cells with nuclear receptors and their ligands
- P-gp induction can also be seen at protein and functional levels
- CYP3A4 protein level and activity remain very modest

# Acknowledgements

- Supervisors: Professor Jukka Mönkkönen, Professor Paavo Honkakoski
- Fellow PhD-students: Joni Palmgrén, Heidi Kemiläinen, Mika Reinisalo
- Technical assistance: Paula Nyyssönen, Markku Taskinen
- Collaboration: Professor Pelkonen's group (Univ. Oulu, Finland)
- Funding: Finnish Funding Agency for Technology and Innovation (TEKES)